OBJECTIVE: The objective of this study was to prospectively assess physical and biochemical cardiovascular risk markers in women who had developed preeclampsia (PE) at 1 year postpartum. STUDY DESIGN: Following an overnight fast, previously PE (n = 70) and normotensive women (n = 70) had weight and blood pressure recorded and levels of morning blood for insulin, glucose, C-reactive protein, lipids, cholesterol, and urine for microalbumin and creatinine measured. Body mass index, homeostatic model assessment index, and incidence of metabolic syndrome were determined. RESULTS: At 1 year postpartum, markers of cardiovascular disease were different between the groups. There were also differences in the number of women with abnormal values. Mathematical modeling of cardiovascular event risk suggests that PE increases the risk by 2- to 3-fold; the risk was greatest for women with severe PE. CONCLUSION: The development of PE is 1 of the earliest clinically identifiable markers of a woman's heightened risk of cardiovascular disease.
OBJECTIVE: The objective of this study was to prospectively assess physical and biochemical cardiovascular risk markers in women who had developed preeclampsia (PE) at 1 year postpartum. STUDY DESIGN: Following an overnight fast, previously PE (n = 70) and normotensive women (n = 70) had weight and blood pressure recorded and levels of morning blood for insulin, glucose, C-reactive protein, lipids, cholesterol, and urine for microalbumin and creatinine measured. Body mass index, homeostatic model assessment index, and incidence of metabolic syndrome were determined. RESULTS: At 1 year postpartum, markers of cardiovascular disease were different between the groups. There were also differences in the number of women with abnormal values. Mathematical modeling of cardiovascular event risk suggests that PE increases the risk by 2- to 3-fold; the risk was greatest for women with severe PE. CONCLUSION: The development of PE is 1 of the earliest clinically identifiable markers of a woman's heightened risk of cardiovascular disease.
Authors: B Anne Croy; Suzanne D Burke; Valerie F Barrette; Jianhong Zhang; Kota Hatta; Graeme N Smith; Juares Bianco; Aureo T Yamada; Michael A Adams Journal: Pregnancy Hypertens Date: 2011-01-01 Impact factor: 2.899
Authors: Darcy R Barry; Kristina M Utzschneider; Jenny Tong; Kersten Gaba; Daniel F Leotta; John D Brunzell; Thomas R Easterling Journal: Am J Obstet Gynecol Date: 2015-05-21 Impact factor: 8.661
Authors: Suzanne D Burke; Valérie F Barrette; Alexandra L Carter; Jonathan Gravel; Michael A Adams; B Anne Croy Journal: Biol Reprod Date: 2011-05-25 Impact factor: 4.285
Authors: Nicole M Ventura; Terry Y Li; M Yat Tse; Logan Richard; Chandrakant Tayade; Albert Y Jin; R David Andrew; Stephen C Pang Journal: Mol Cell Biochem Date: 2018-05-25 Impact factor: 3.396
Authors: David W J Armstrong; M Yat Tse; Philip G Wong; Nicole M Ventura; Jalna A Meens; Amer M Johri; Murray F Matangi; Stephen C Pang Journal: Mol Cell Biochem Date: 2014-04-10 Impact factor: 3.396